CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Nature Reviews Drug Discovery
High ImpactOriginal article

FDA approves second IGF-1R-targeted antibody for thyroid eye disease

RegulatoryapprovedPositive
AI Analysis

Summary

The FDA has approved a second IGF-1R-targeted antibody for the treatment of thyroid eye disease, expanding therapeutic options in this indication.

Outcome Details

FDA approval of second IGF-1R-targeted antibody

Importance:8/10
Sentiment:
0.80
FDA approvalIGF-1R antibodythyroid eye diseasesecond-in-class

Read the original article

Published by Nature Reviews Drug Discovery on July 8, 2026 12:00 AM

Read Original